Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).

被引：0
|
作者：
Forster, Martin
Calvo, Emiliano
Olmedo Garcia, Maria Eugenia
Pilar Lopez Criado, M.
Moreno, Victor
Soto-Matos, Arturo
Holgado, Esther
Brown, Nicholas F.
Flynn, Michael
Boni, Valentina
Guerra Alia, Eva
Szyldergemajn, Sergio A.
机构：
[1] UCL, London, England
[2] START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain
[3] Ramon & Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
[4] MD Anderson Canc Ctr Madrid, Madrid, Spain
[5] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[6] PharmaMar SAU, Madrid, Spain
[7] Hosp Madrid, Norte Sanchinarro, Spain
[8] Hosp Univ Ramon & Cajal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CLINICAL ACTIVITY OF LURBINECTEDIN (PM01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
    Forster, M.
    Calvo, E.
    Szyldergemajn, S.
    Boni, V.
    Benafif, S.
    Fernandez, C.
    Turnbull, S.
    Cubillo, A.
    Flynn, M.
    Velasco Sampayo, A.
    Soto Matos-Pita, A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S633 - S633
  • [2] SCLC: second-line therapy with lurbinectedin and doxorubicin on trial
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (10):
  • [3] Lurbinectedin (PM01183) synergizes in vivo the antitumor activity of doxorubicin in SCLC tumor xenografts
    Jose Guillen, Maria
    Cataluna, Oscar
    Palomares, Mandy
    Lopez, Raquel
    Nunez, Praxedes
    Cuevas, Carmen
    Aviles, Pablo M.
    CANCER RESEARCH, 2015, 75
  • [4] COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Su, W.
    Rengarajan, B.
    Profant, D.
    Mayo, K.
    Groff, M.
    Tremblay, G.
    Ganti, A. K.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [5] Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
    Calvo, E.
    Moreno, V.
    Flynn, M.
    Holgado, E.
    Olmedo, M. E.
    Criado, M. P. Lopez
    Kahatt, C.
    Lopez-Vilarino, J. A.
    Siguero, M.
    Fernandez-Teruel, C.
    Cullell-Young, M.
    Matos-Pita, A. Soto
    Forster, M.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2559 - 2566
  • [6] An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
    Patel, Shetal
    Petty, William Jeffrey
    Sands, Jacob M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [7] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [8] Second-line chemotherapy for small-Cell Lung Cancer (SCLC)
    Kim, Young Hak
    Mishima, Michiaki
    CANCER TREATMENT REVIEWS, 2011, 37 (02) : 143 - 150
  • [9] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Cheng, Ying
    Wu, Chunjiao
    Wu, Lin
    Zhao, Jun
    Zhao, Yanqiu
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinhua
    Li, Xingya
    Li, Juan
    Dong, Xiaorong
    Tang, Ke
    Gao, Emei
    Yu, Fei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [10] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Ying Cheng
    Chunjiao Wu
    Lin Wu
    Jun Zhao
    Yanqiu Zhao
    Lulu Chen
    Ying Xin
    Liang Zhang
    Pinhua Pan
    Xingya Li
    Juan Li
    Xiaorong Dong
    Ke Tang
    Emei Gao
    Fei Yu
    Scientific Reports, 14
12345